HLB Fails in Third FDA Bid—Can It Rebuild Shattered Market Trust?

HLB’s liver cancer drug rivoceranib, which the company has developed for more than two decades, has once again failed to clear the U.S. Food and Drug Administration’s approval hurdle on its third attempt.As in the previous reviews, the setback was not attributed to clinical trial results but to manu